Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Fampridine – Benefit assessment according to § 35a Social Code Book V
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Forsythiaside A Exhibits Anti-inflammatory Effects in LPS-Stimulated BV2 Microglia Cells Through Activation of Nrf2/HO-1 Signaling Pathway.
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide.
Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)
Multiple sclerosis relapses and depression.
Overview of treatment options in multiple sclerosis.
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.
Oligoclonal band and multiple sclerosis risk in monosymptomatic optic neuritis patients: a retrospective study of 84 patients.
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
Safety and efficacy extension study of daclizumab high yield process (DAC HYP) to treat relapsing remitting multiple sclerosis
Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis.
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: No.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis.
Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
The benefits of exercise training in multiple sclerosis.
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.

Pages